Search clinical trials for: REGN5714

Total 4 results

Regeneron Pharmaceuticals

Completed

Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen in Adult Participants

Conjunctivitis | Allergic Rhinitis

Canada
Regeneron Pharmaceuticals

Completed

Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic Rhinitis

Conjunctivitis | Allergic Rhinitis

United States, Belgium, Canada, Denmark, Germany
Regeneron Pharmaceuticals

Completed

Study to Assess the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of a Single Dose of REGN5713-5714-5715 in Healthy Adult Participants

Healthy Volunteers | Birch Pollen Allergy

Belgium
Regeneron Pharmaceuticals

Active, not recruiting

A Trial to Learn if Different Doses of REGN7544 Are Safe in Healthy Adult Participants

Healthy Volunteers

New Zealand

3

Subscribe